[Skip to Content]
[Skip to Content Landing]
Views 1,466
Citations 0
July 9, 2020

Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer: Positive, Negative, or a More Complex Issue?

Author Affiliations
  • 1Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • 2Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
JAMA Oncol. 2020;6(9):1332-1333. doi:10.1001/jamaoncol.2020.2285

Liquid biopsies are tools to examine tumors released into the peripheral blood and include cell-free DNA, a fraction of which consists of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and/or proteins. Consistent across studies, shedding tumors can actively or passively release DNA or CTCs into the blood and are associated with worse clinical outcome compared with nonshedding tumors. In metastatic breast cancer, CTC enumeration, at a well-established threshold, stratifies patients’ disease into indolent and aggressive classifications across pathologic subtypes, serving as the most significant negative factor associated with overall survival in multivariate analysis.1 Similarly, a higher ctDNA mutant allele frequency is associated with worse outcome for patients with advanced breast cancer.2 Compared with metastatic disease, early-stage cancers have a lower tumor burden, which presents a challenge to identify tumors in the blood for patients without distant metastasis based on standard clinical and imaging assessments. Evaluation of this minimal residual disease (MRD) in the blood has the potential to change the treatment paradigm of early-stage cancers.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words